中华老年医学杂志
中華老年醫學雜誌
중화노년의학잡지
Chinese Journal of Geriatrics
2013年
4期
426-429
,共4页
张闰%刘娟%葛峥%柳萍%林忠琨%乔纯%仇海荣%朱广荣%吴雨洁
張閏%劉娟%葛崢%柳萍%林忠琨%喬純%仇海榮%硃廣榮%吳雨潔
장윤%류연%갈쟁%류평%림충곤%교순%구해영%주엄영%오우길
白血病,淋巴样%免疫表型分型
白血病,淋巴樣%免疫錶型分型
백혈병,림파양%면역표형분형
Leukemia,lymphoid%Immunophenotyping
目的 探讨老年人急性淋巴细胞白血病(ALL)临床、实验室特征,及针对性治疗策略.方法 收集本院ALL患者162例,按年龄分为老年组、中年组及青年组,对不同年龄组患者进行回顾性对照研究. 结果 随年龄增长Philadelphia染色体阳性(Ph+)率呈上升趋势,老年组、中年组及青年组分别为45.5％、28.8％和23.7％,老年组显著高于青年组(P=0.047)；老年组CD19和CD33阳性率分别为94.4％和81.8％,高于中、青年组(71.6％和44.6％,P=0.039和P=0.021)；老年组淋巴结肿大发生率显著低于其他年龄组(12.0％、34.3％和46.7％,P=0.014)；老年组诱导缓解化疗后完全缓解率低于其他年龄组(55.0％、72.7％和85.2％,P=0.024)；老年组总生存时间显著短于青年组(8个月和17个月,P=0.035). 结论 老年ALL患者具有不同于非老年患者的特征,应引起高度重视,加强认识,尽早发现高危亚型,采取针对性靶向治疗.
目的 探討老年人急性淋巴細胞白血病(ALL)臨床、實驗室特徵,及針對性治療策略.方法 收集本院ALL患者162例,按年齡分為老年組、中年組及青年組,對不同年齡組患者進行迴顧性對照研究. 結果 隨年齡增長Philadelphia染色體暘性(Ph+)率呈上升趨勢,老年組、中年組及青年組分彆為45.5％、28.8％和23.7％,老年組顯著高于青年組(P=0.047)；老年組CD19和CD33暘性率分彆為94.4％和81.8％,高于中、青年組(71.6％和44.6％,P=0.039和P=0.021)；老年組淋巴結腫大髮生率顯著低于其他年齡組(12.0％、34.3％和46.7％,P=0.014)；老年組誘導緩解化療後完全緩解率低于其他年齡組(55.0％、72.7％和85.2％,P=0.024)；老年組總生存時間顯著短于青年組(8箇月和17箇月,P=0.035). 結論 老年ALL患者具有不同于非老年患者的特徵,應引起高度重視,加彊認識,儘早髮現高危亞型,採取針對性靶嚮治療.
목적 탐토노년인급성림파세포백혈병(ALL)림상、실험실특정,급침대성치료책략.방법 수집본원ALL환자162례,안년령분위노년조、중년조급청년조,대불동년령조환자진행회고성대조연구. 결과 수년령증장Philadelphia염색체양성(Ph+)솔정상승추세,노년조、중년조급청년조분별위45.5％、28.8％화23.7％,노년조현저고우청년조(P=0.047)；노년조CD19화CD33양성솔분별위94.4％화81.8％,고우중、청년조(71.6％화44.6％,P=0.039화P=0.021)；노년조림파결종대발생솔현저저우기타년령조(12.0％、34.3％화46.7％,P=0.014)；노년조유도완해화료후완전완해솔저우기타년령조(55.0％、72.7％화85.2％,P=0.024)；노년조총생존시간현저단우청년조(8개월화17개월,P=0.035). 결론 노년ALL환자구유불동우비노년환자적특정,응인기고도중시,가강인식,진조발현고위아형,채취침대성파향치료.
Objective To analyze the clinical and laboratory features of acute lymphoblastic leukemia (ALL) in elderly patients and to discuss its targeted therapy.Methods A retrospective study was performed to evaluate elderly patients (over 60 years old,n=162) with ALL.The patients were divided into 3 groups according to age:elderly group (60～79 years old,n=26),middle-age group (40～59 years old,n=56) and young group (18～39 years old,n=80).Results The incidence of Philadelphia-positive (Ph+) was increased with aging in the 3 groups (23.7 ％,28.8 ％ and 45.5 ％,respectively) and there was a significant difference in the incidence between the elderly group and young group (P=0.047).The expressions of CD19 and CD33 were higher in elderly group than in thc young and middle-age groups(94.4％ vs.71.6％,P=0.039;81.8％ vs.44.6％,P=0.021).The incidence of enlarged lymph nodes was lower in elderly group than in young and middle-age groups (12.0％,34.3％ and 46.7％,respectively,P=0.014).Complete remission rate in elderly group was lower than in young and middle-age group (55.0％,72.7％ and 85.2％,respectively,P=0.024).The overall survival time was significantly lower in elderly group than in young group (median overall survival was 8 and 17 months,respectively,P=0.035).Conclusions Elderly patients with ALL is a unique subgroup with high-risk,a great attention should be paid to it.The targeted therapy should be applied as early as possible.
